Proteomic Profiling to Differentiate Pancreatic and Biliary Adenocarcinomas

Launched by UNIVERSITY HOSPITAL, BORDEAUX · Jan 9, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to help doctors tell the difference between two types of aggressive cancers: pancreatic adenocarcinoma and distal cholangiocarcinoma. These cancers can look very similar under a microscope, which can lead to confusion in diagnosis. Since they require different treatments after surgery, it's crucial to identify which cancer a patient has accurately. The study will use a method called proteomic profiling, which analyzes proteins in the body to provide more precise information about the type of cancer.

To participate in this trial, individuals must be at least 18 years old and have undergone a specific surgical procedure for either pancreatic adenocarcinoma or distal cholangiocarcinoma. The trial is not yet recruiting participants, but it aims to help improve the accuracy of cancer diagnoses and ensure patients receive the right treatment. If you or someone you know is facing these conditions, this trial could contribute to a better understanding of how to differentiate between these cancers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients ≥ 18 years old
• • Pancreaticoduodenectomy for pancreatic adenocarcinoma or distal cholangiocarcinoma
• • Patient's non-opposition to the reuse of data
• Exclusion Criteria:
• • Neoadjuvant chemotherapy
• • Patients under legal protection